Lalistat 2
Based on 3 publication(s) in Google Scholar
Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC50 = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells .
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 1234569-09-5
- Formula: C13H20N4O2S
- Molecular Weight:296.39
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Lalistat 2
More
Customer Validation & Images
-
Cell Imaging/Staining
-
Flow Cytometry
-
WB
-
Microbiological Assay
-
Bio/Physico-chemical Assay
Biological Activity
IC50: 152 nM (LAL)[2]
Lalistat 2 (30 μM, 7 d) does not affect differentiation of mice adipocytes but reduces isoproterenol-stimulated lipolysis[1].
Lalistat 2 (30 μM, 7 d) inhibits neutral lipid hydrolase activity in mice adipocytes[1].
Lalistat 2 (0.1-100 μM, 20 h) inhibits neutral lipid hydrolases in bone marrow-derived macrophages (BMDM) in a dose-dependent manner[1].
Lalistat 2 (30 μM, 24 h) inhibits adipose triglyceride lipase and hormone-sensitive lipase in mouse and human COS-7 cells[1].
Lalistat 2 (30 μM, 20 h) decreases activities of LAL， ATGL， HSL， MGL， PNPLA6 and NCEH1 in mice bone marrow-derived macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1234569-09-5
-
Appearance Solid
-
Molecular Weight 296.39
-
Formula C13H20N4O2S
-
Color White to off-white
-
SMILES
O=C(N1CCCCC1)OC2=NSN=C2N3CCCCC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
2026 Mar 11:1-18. PMID: 41810751
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 11:1-18. [Abstract]
A549 cells pretreated with 200 μM OA for 6 h were infected with La Sota (MOI = 1) and treated simultaneously with CQ (10 mM) or Lalistat 2 (20 μM). Cells were fixed at 18 hpi. Pseudocolor was applied to distinguish the fluorescence channels: LDs, nuclei, and infected cells are shown in red, blue, and gray, respectively. Scale bar = 10 μm.
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 11:1-18. [Abstract]
A549 cells pretreated with 200 μM OA for 6 h were infected with La Sota (MOI = 1) and simultaneously treated with CQ (10 mM) or Lalistat 2 (20 μM). The cells were analyzed by flow cytometry at 24 hpi; LDs were labeled with BODIPY, and the mean intracellular fluorescence intensity was quantified.
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 11:1-18. [Abstract]
A549 cells infected with La Sota (MOI = 1) and treated with Lalistat 2 (20 μM) were collected at 24 hpi. PLIN2 and LC3 protein levels were determined by western blot; PLIN2 was used to quantify LD content, NP served as a marker of infection, and changes in LC3 reflected the effects of virus and inhibitors on autophagy.
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 11:1-18. [Abstract]
A549 cells were infected with Herts/33 (MOI = 0.01) and treated with Lalistat 2 (5-80 μM) at the indicated concentrations. Cells were collected at 18 hpi, and virus yield in supernatants was determined by viral plaque assay.
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Autophagy. 2026 Mar 11:1-18. [Abstract]
A549 cells were treated with 13C-labeled OA (50 μM) for 6 h to induce LD formation, then infected with Herts/33 (MOI = 1). Cells were collected at 18 hpi, and PC 34:2, PC 36:1, PC 36:2, PC 38:1, and PC 38:2 were detected by LC-MS. The results showed that incorporation of OA into PC 34:2, PC 36:1, PC 36:2, PC 38:1, and PC 38:2 was significantly higher in infected cells than in controls, and this increase was abolished by Lalistat 2 (20 μM; 18 h) treatment.
-
Proc Natl Acad Sci U S A
A PIKfyve modulator combined with an integrated stress response inhibitor to treat lysosomal storage diseases. [Abstract]2024 Aug 20;121(34):e2320257121. PMID: 39150784 -
Biochim Biophys Acta Mol Basis Dis
Exercise ameliorates lipid droplet metabolism disorder by the PLIN2-LIPA axis-mediated lipophagy in mouse model of non-alcoholic fatty liver disease. [Abstract]2024 Mar;1870(3):167045. PMID: 38306800
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167045. [Abstract]
Lalistat 2 (20 μM; 24 h). Representative images of HepG2 cells stained with Nile red staining (red) (20 × objective, scale bar: 100 μm). The resuls showed that LIPA has a critical effect on lipophagy.
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167045. [Abstract]
Lalistat 2 (20 μM; 24 h). Immunoblot of autophagy markers in HepG2 cells. Quantitative analyses of the LC3II/LC3I, P62 and expression ratios are shown in HepG2 cells using western blotting assay.
Lalistat 2 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167045. [Abstract]
The mRNA transcription and expression of P62 and LC3II in HepG2 cells cultured in the presence or absence of PA (200 μM) or PA plus Lalistat 2 (20 μM; 24 h) (inhibitor of LIPA). The results showed that the mRNA levels of P62 increased, and LC3II decreased after PA treatment.
Solvent & Solubility
DMSO : ≥ 100 mg/mL (337.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bradić I, et al. Off-target effects of the lysosomal acid lipase inhibitors Lalistat-1 and Lalistat-2 on neutral lipid hydrolases. Mol Metab. 2022，61，101519. [Content Brief]
[2]. Rosenbaum AI, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J Med Chem. 2010, 53(14):5281-9. [Content Brief]
[3]. Lukacs Z, et al. Best practice in the measurement and interpretation of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2017;471:201-205. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3739 mL | 16.8697 mL | 33.7393 mL | 84.3483 mL |
| 5 mM | 0.6748 mL | 3.3739 mL | 6.7479 mL | 16.8697 mL | |
| 10 mM | 0.3374 mL | 1.6870 mL | 3.3739 mL | 8.4348 mL | |
| 15 mM | 0.2249 mL | 1.1246 mL | 2.2493 mL | 5.6232 mL | |
| 20 mM | 0.1687 mL | 0.8435 mL | 1.6870 mL | 4.2174 mL | |
| 25 mM | 0.1350 mL | 0.6748 mL | 1.3496 mL | 3.3739 mL | |
| 30 mM | 0.1125 mL | 0.5623 mL | 1.1246 mL | 2.8116 mL | |
| 40 mM | 0.0843 mL | 0.4217 mL | 0.8435 mL | 2.1087 mL | |
| 50 mM | 0.0675 mL | 0.3374 mL | 0.6748 mL | 1.6870 mL | |
| 60 mM | 0.0562 mL | 0.2812 mL | 0.5623 mL | 1.4058 mL | |
| 80 mM | 0.0422 mL | 0.2109 mL | 0.4217 mL | 1.0544 mL | |
| 100 mM | 0.0337 mL | 0.1687 mL | 0.3374 mL | 0.8435 mL |
Powered by Bioz